GNNSF (Genscript Biotech) Total Current Assets: $1,079.0 Mil (As of Dec. 2025)


GNNSF Genscript Biotech Corp GNNSF
66 GF Score
Price $1.60
GF Value $2.50
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genscript Biotech Total Current Assets?

Genscript Biotech GNNSF 66 Total Current Assets is $1,079.0 Mil as of Dec. 2025. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.50 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Genscript Biotech's total current assets for the quarter that ended in Dec. 2025 was $1,079.0 Mil.


Genscript Biotech  (OTCPK:GNNSF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Genscript Biotech's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=811.99-888.587+0.75 * 130.223+0.5 * 39.594
=40.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genscript Biotech Total Current Assets Related Terms


Genscript Biotech Total Current Assets Historical Data

* Premium members only.

The historical data trend for Genscript Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genscript Biotech Total Current Assets Chart

Genscript Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,639.06 1,764.95 2,353.11 834.98 1,078.97

Genscript Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,353.11 2,214.32 834.98 1,176.81 1,078.97
GNNSF
66GF Score
Genscript Biotech Corp GNNSF
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genscript Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Genscript Biotech's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Genscript Biotech's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $1,079.0 Mil mean?
Genscript Biotech (GNNSF) has a Total Current Assets of $1,079.0 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Genscript Biotech and its competitors.
Is Genscript Biotech's Total Current Assets too high?
Genscript Biotech's current Total Current Assets is $1,079.0 Mil. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Total Current Assets compare to VRTX and REGN?
Genscript Biotech's Total Current Assets of $1,079.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Genscript Biotech and its competitors. Genscript Biotech's current Total Current Assets is $1,079.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.50, compared to a current price of $1.60 — trading 36% below its estimated fair value. The current Total Current Assets is $1,079.0 Mil. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Total Current Assets is $1,079.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (GNNSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of $1.60 is trading 36% below its estimated GF Value™ of $2.50. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for GNNSF:

  • Total Current Assets: $1,079.0 Mil
  • GF Value™: $2.50 vs. price of $1.60 (36% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genscript Biotech Business Description

Other Exchanges 01548:Hong KongG51:Germany
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score

Get the complete analysis for GNNSF

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price
$2.50
GF Value